Susquehanna International Group, LLP Caribou Biosciences, Inc. Put Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 15, 2024
SELL
$1.62 - $5.05 $85,536 - $266,640
-52,800 Reduced 73.13%
19,400 $31,000
Q1 2024

May 07, 2024
BUY
$4.82 - $8.26 $205,332 - $351,876
42,600 Added 143.92%
72,200 $371,000
Q4 2023

Feb 14, 2024
SELL
$3.58 - $6.25 $122,794 - $214,375
-34,300 Reduced 53.68%
29,600 $169,000
Q3 2023

Nov 14, 2023
BUY
$4.08 - $8.14 $260,712 - $520,146
63,900 New
63,900 $305,000
Q3 2022

Nov 14, 2022
BUY
$5.34 - $12.79 $35,244 - $84,414
6,600 Added 24.54%
33,500 $353,000

Others Institutions Holding CRBU

# of Institutions
145
Shares Held
53.7M
Call Options Held
32.5K
Put Options Held
89.8K
View Full List

About Caribou Biosciences, Inc.

CRBU Quotes by TradingView
  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email